On November 10, 2022, the Federal Trade Commission announced a significant change in how the FTC plans to enforce Section 5 of the FTC Act, which bans "unfair methods of competition in or affecting commerce." In doing so, the...more
2/1/2024
/ Antitrust Violations ,
Chamber of Commerce ,
Competition ,
Corporate Counsel ,
Enforcement Actions ,
Federal Trade Commission (FTC) ,
FTC Act ,
Non-Compete Agreements ,
Policies and Procedures ,
Popular ,
Regulatory Reform ,
Section 5 ,
Unfair Competition
On February 3, 2020, the Federal Trade Commission ("FTC") and the Food and Drug Administration ("FDA") issued a joint statement and plan seeking to advance biosimilar competition and combat deceptive and anticompetitive...more
2/14/2020
/ Anticompetitive Behavior ,
Antitrust Litigation ,
Antitrust Violations ,
Biologics ,
Biosimilars ,
Class Action ,
Federal Trade Commission (FTC) ,
Food and Drug Administration (FDA) ,
Joint Statements ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Popular ,
Reverse Payment Settlement Agreements ,
Unfair or Deceptive Trade Practices